Evaluating the toxicity of nanomedicines involves a combination of in vitro and in vivo studies. In vitro tests assess cytotoxic effects on cultured cells, while in vivo studies in animal models provide data on absorption, distribution, metabolism, excretion, and potential toxic effects. Regulatory agencies like the FDA and EMA require rigorous testing to ensure that nanomedicines meet safety standards before they can be marketed.
